Dr Gerd Zettlmeissl represents Aeras as member of the Board of Directors of Aeras. He is the former CEO of the Austrian-based biotechnology company Valneva SE (formerly Intercell AG), and is an accomplished vaccine expert and biopharmaceutical business executive. Dr. Zettlmeissl has more than 25 years of scientific and leadership experience in the biopharmaceutical industry. While at Intercell AG from 2001 to 2011, he built the company from a private start up venture to a publicly listed international organization with more than 400 employees. As CEO, he secured regulatory approval for and led the launch of an improved Japanese Encephalitis vaccine, and oversaw efforts to build and advance a broad based development portfolio of vaccines. Prior to joining Intercell, Dr. Zettlmeissl held senior management roles at Chiron Corp and Behringwerke AG. In 2010, he was named Vaccine Biotech CEO of the Year at the World Vaccine Congress.